# Natalizumab Re-Initiation of Dosing

> **NCT00306592** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 404 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** BG00002 (natalizumab)

## Key facts

- **NCT ID:** NCT00306592
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-12
- **Final completion:** 2008-02
- **Target enrollment:** 404 (ACTUAL)
- **Last updated:** 2017-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00306592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00306592, "Natalizumab Re-Initiation of Dosing". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00306592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*